MA39319A1 - Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires - Google Patents
Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculairesInfo
- Publication number
- MA39319A1 MA39319A1 MA39319A MA39319A MA39319A1 MA 39319 A1 MA39319 A1 MA 39319A1 MA 39319 A MA39319 A MA 39319A MA 39319 A MA39319 A MA 39319A MA 39319 A1 MA39319 A1 MA 39319A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- cardiovascular disease
- treatment
- cetp
- transfer protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) pour son utilisation dans le traitement de sujets souffrant de maladies cardiovasculaires ou présentant un risque accru de maladies cardiovasculaires, en particulier l'hyperlipidémie ou la dyslipidémie mixte. Un autre aspect de la présente invention concerne une composition pharmaceutique pour son utilisation dans le traitement de sujets souffrant de maladies cardiovasculaires ou présentant un risque accru de maladies cardiovasculaires, la composition comprenant une quantité thérapeutiquement efficace dudit inhibiteur de cetp.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2014/050068 WO2015119495A1 (fr) | 2014-02-05 | 2014-02-05 | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39319A1 true MA39319A1 (fr) | 2017-07-31 |
Family
ID=50116144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39319A MA39319A1 (fr) | 2014-02-05 | 2014-02-05 | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US10653692B2 (fr) |
| EP (1) | EP3102212B1 (fr) |
| JP (1) | JP6263271B2 (fr) |
| KR (1) | KR101967970B1 (fr) |
| CN (5) | CN112755031A (fr) |
| AP (1) | AP2016009359A0 (fr) |
| AR (1) | AR099299A1 (fr) |
| AU (1) | AU2014381733B2 (fr) |
| BR (1) | BR112016018077A8 (fr) |
| CA (1) | CA2938718C (fr) |
| CR (1) | CR20160353A (fr) |
| CY (1) | CY1121707T1 (fr) |
| DK (1) | DK3102212T3 (fr) |
| EA (1) | EA032689B1 (fr) |
| ES (1) | ES2710104T3 (fr) |
| HR (1) | HRP20190211T1 (fr) |
| HU (1) | HUE042932T2 (fr) |
| IL (1) | IL247037A (fr) |
| LT (1) | LT3102212T (fr) |
| MA (1) | MA39319A1 (fr) |
| ME (1) | ME03295B (fr) |
| MX (1) | MX369471B (fr) |
| PH (1) | PH12016501548A1 (fr) |
| PL (1) | PL3102212T3 (fr) |
| PT (1) | PT3102212T (fr) |
| RS (1) | RS58329B1 (fr) |
| SG (1) | SG11201605956RA (fr) |
| SI (1) | SI3102212T1 (fr) |
| TW (1) | TWI651086B (fr) |
| UA (1) | UA120922C2 (fr) |
| WO (1) | WO2015119495A1 (fr) |
| ZA (1) | ZA201605490B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014381733B2 (en) | 2014-02-05 | 2020-09-03 | Newamsterdam Pharma B.V. | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
| WO2016032324A1 (fr) * | 2014-08-28 | 2016-03-03 | Dezima Pharma B.V. | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
| WO2022177428A1 (fr) * | 2021-02-18 | 2022-08-25 | Newamsterdam Pharma B.V. | Polythérapie d'obicétrapib et d'ézétimibe destinée à être utilisée chez des patients intolérants à la statine souffrant d'hyperlipidémie ou de dyslipidémie mixte |
| BR112023017999A2 (pt) * | 2021-03-05 | 2023-11-14 | Newamsterdam Pharma B V | Obicetrapibe para tratamento de demências |
| WO2024009144A1 (fr) | 2022-07-05 | 2024-01-11 | Newamsterdam Pharma B.V. | Sels d'obicetrapib et leurs procédé de fabrication et leurs intermédiaires |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| EP1761521A1 (fr) * | 2004-06-24 | 2007-03-14 | Eli Lilly And Company | Composés et procédés destinés à traiter la dyslipidémie |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| JP4531027B2 (ja) * | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CN101553221A (zh) * | 2006-10-10 | 2009-10-07 | 瑞莱恩特医药品有限公司 | 用于降低APO-B水平的抑制素和ω-3脂肪酸 |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| AU2014381733B2 (en) * | 2014-02-05 | 2020-09-03 | Newamsterdam Pharma B.V. | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
| WO2016032324A1 (fr) * | 2014-08-28 | 2016-03-03 | Dezima Pharma B.V. | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
-
2014
- 2014-02-05 AU AU2014381733A patent/AU2014381733B2/en active Active
- 2014-02-05 EA EA201691572A patent/EA032689B1/ru not_active IP Right Cessation
- 2014-02-05 ES ES14705225T patent/ES2710104T3/es active Active
- 2014-02-05 PT PT14705225T patent/PT3102212T/pt unknown
- 2014-02-05 CN CN202011468410.0A patent/CN112755031A/zh active Pending
- 2014-02-05 EP EP14705225.2A patent/EP3102212B1/fr active Active
- 2014-02-05 MX MX2016010212A patent/MX369471B/es active IP Right Grant
- 2014-02-05 KR KR1020167024380A patent/KR101967970B1/ko active IP Right Grant
- 2014-02-05 CN CN202110492605.7A patent/CN113332288A/zh active Pending
- 2014-02-05 BR BR112016018077A patent/BR112016018077A8/pt not_active Application Discontinuation
- 2014-02-05 HU HUE14705225A patent/HUE042932T2/hu unknown
- 2014-02-05 UA UAA201609188A patent/UA120922C2/uk unknown
- 2014-02-05 CN CN201911087834.XA patent/CN110721187A/zh active Pending
- 2014-02-05 JP JP2016550780A patent/JP6263271B2/ja active Active
- 2014-02-05 US US15/117,154 patent/US10653692B2/en active Active
- 2014-02-05 AP AP2016009359A patent/AP2016009359A0/en unknown
- 2014-02-05 LT LTEP14705225.2T patent/LT3102212T/lt unknown
- 2014-02-05 ME MEP-2019-27A patent/ME03295B/fr unknown
- 2014-02-05 CN CN202110492572.6A patent/CN113332287A/zh active Pending
- 2014-02-05 MA MA39319A patent/MA39319A1/fr unknown
- 2014-02-05 CR CR20160353A patent/CR20160353A/es unknown
- 2014-02-05 RS RS20190122A patent/RS58329B1/sr unknown
- 2014-02-05 CA CA2938718A patent/CA2938718C/fr active Active
- 2014-02-05 CN CN201480074940.3A patent/CN106232121A/zh active Pending
- 2014-02-05 WO PCT/NL2014/050068 patent/WO2015119495A1/fr active Application Filing
- 2014-02-05 SG SG11201605956RA patent/SG11201605956RA/en unknown
- 2014-02-05 DK DK14705225.2T patent/DK3102212T3/en active
- 2014-02-05 PL PL14705225T patent/PL3102212T3/pl unknown
- 2014-02-05 SI SI201431043T patent/SI3102212T1/sl unknown
-
2015
- 2015-02-04 TW TW104103678A patent/TWI651086B/zh active
- 2015-02-05 AR ARP150100338A patent/AR099299A1/es unknown
-
2016
- 2016-08-01 IL IL247037A patent/IL247037A/en active IP Right Grant
- 2016-08-04 PH PH12016501548A patent/PH12016501548A1/en unknown
- 2016-08-08 ZA ZA2016/05490A patent/ZA201605490B/en unknown
-
2019
- 2019-01-17 CY CY20191100064T patent/CY1121707T1/el unknown
- 2019-01-31 HR HRP20190211TT patent/HRP20190211T1/hr unknown
-
2020
- 2020-04-09 US US16/844,996 patent/US11013742B2/en active Active
-
2021
- 2021-04-09 US US17/226,655 patent/US11642344B2/en active Active
-
2023
- 2023-04-03 US US18/130,178 patent/US20240024315A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA40755B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA40754B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA41060B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA55434A (fr) | Compositions comprenant des souches bactériennes | |
| MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| MA41010B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA47043A1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
| MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA39319A1 (fr) | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires | |
| MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA47442A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| PH12019501682A1 (en) | Rorgamma modulators and uses thereof | |
| MA52129B1 (fr) | Compositions compositions de flagelline d'enterococcus pour une utilisation thérapeutique | |
| MA50273A (fr) | Compositions comprenant des souches bactériennes |